Effects of dopaminergic drugs on inflammatory bowel disease induced with 2,4-dinitrofluorbenzene in BALB/c mice.
The aim of the study was to demonstrate the effects of dopaminergic drugs on 2,4-dinitrofluorbenzene (DNFB) induced experimental inflammatory bowel disease (IBD) in previously sensitized BALB/c mice. The number and extent of ulcerations and erosions, the intensity of haemorrhages, oedema, and accumulation of neutrophils and eosinophils within colonic lamina propria and submucosa were scored and statistically evaluated. The 180 BALB/c mice, were allocated into three equal groups. The mice in the first experimental group were treated with domperidone (DP), a peripheral dopamine (DA) antagonist. The mice from the second experimental group were treated with bromocriptine (BC), a dopamine agonist. The mice from the control group were treated with an equivalent volume of normal saline in the same manner. Ten animals from each group were killed on days 1, 2, 3, 5 and 10, subsequent to the challenge enema of DNFB solution. Gross and microscopic examination of the colon was performed. Treatment with BC resulted in clinical improvement and decreased mortality rate by 2 of 60 (3%), while domperidone treatment increased mortality rate to 12 of 60 (20%) compared with the controls [4 of 60 (6%)]. The analysis of the microscopic lesions indicated that the beneficial effects of BC were the result of maintenance of vascular integrity.
Herak-Perković
V
V
VETERINA, Animal Health Ltd, Svetonedjeljska 2, 10436 Rakov Potok, Croatia.
Grabarević
Z
Z
Banić
M
M
Anić
B
B
Novosel
V
V
Pogacnik
M
M
D000818:Animals; D001971:Bromocriptine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003106:Colon / Q000187:drug effects; D004139:Dinitrofluorobenzene; D004195:Disease Models, Animal; D004294:Domperidone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011897:Random Allocation
D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D001971:Bromocriptine; D004294:Domperidone; D004139:Dinitrofluorobenzene